BioCentury | Apr 10, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

...disease Atherosclerosis Peroxisome proliferation-activated receptor-g (PPARG; PPARg); myeloid-lymphoma or mixed-lineage 5 (MLL5); 5ʹ-3ʹ exoribonuclease 2 (XRN2...
...expression networks controlled by PPARg in early stages of plaque expansion and by MLL5 and XRN2...
BioCentury | Sep 19, 2013
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease SARS-associated coronavirus Exoribonuclease in nonstructural protein 14 (nsp14-ExoN) In vitro studies suggest nsp14-ExoN inhibitors could help sensitize coronaviruses to RNA mutagen therapeutics including ribavirin....
Items per page:
1 - 2 of 2